TSCAN THERAPEUTICS INC (TCRX) Stock News
NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock - Currency: USD
TCRX Latest News, Press Relases and Analysis
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 7.14% and 34.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: GLUE
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for...
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience...
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in...
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029...
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse...
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial...
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to...
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and...